Sun Pharma gets non-exclusive rights to market second brand of Finerenone in India Ruchika Sharma19 Jan 2024 11:17 AM ISTBayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa.
New Kerendia data show impact of early albuminuria reduction in patients with chronic kidney disease, type 2 diabetes: Bayer Ruchika Sharma4 Nov 2023 3:04 PM ISTBerlin: Bayer has announced new late-breaking Kerendia (finerenone) data from FIDELITY, a prespecified pooled analysis of the Phase III...
Bayer Kerendia granted expanded indication in EU for broad range of patients with chronic kidney disease, type 2 diabetes Ruchika Sharma12 Feb 2023 3:41 PM ISTKerendia is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block harmful effects of MR overactivation.
Finerenone receives Grade A Recommendation for treating CKD patients associated with type 2 diabetes: AACE update Dr. Kamal Kant Kohli10 Dec 2022 8:00 PM ISTUSA: Bayer's KERENDIA (finerenone), a first-in-class non-steroidal mineralocorticoid receptor antagonist (ns-MRA) has received a grade A...
Bayer unveils drug for CKD associated with diabetes under brand name Kerendia Ruchika Sharma26 Aug 2022 11:15 AM ISTThe major focus of therapy in patients with chronic kidney disease and diabetes is to prevent end stage renal disease or kidney failure.
Bayer gets nod for Kerendia to treat type 2 diabetes, CKD in Japan Ruchika Sharma1 April 2022 9:00 AM ISTBerlin: Bayer has recently announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has granted marketing authorization for...
Bayer Finerenone gets USFDA approval to treat CKD associated with type 2 diabetes Ruchika Sharma11 July 2021 10:00 AM ISTBerlin: Bayer has announced that the U.S. Food and Drug Administration (FDA) has approved finerenone, the first non-steroidal, selective...
